Citations

Clear

9383 citation(s) found for "Thomas, PS".

Lowering Kilovoltage to Reduce Radiation Dose in Contrast-Enhanced Abdominal CT: Initial Assessment of a Prototype Automated Kilovoltage Selection Tool
Hough, David M., Grant, Katharine L., Fidler, Jeff L. , Yu, Lifeng , Geske, Jennifer R. , Carter, Rickey E. , Raupach, Rainer , Schmidt, Bernhard , Flohr, Thomas , Fletcher, Joel G. , Fidler, Jeff L. , Yu, Lifeng , McCollough, Cynthia H. , Carter, Rickey E , Geske, Jennifer

Mayo Clinic

American Journal of Roentgenology | October 24, 2012 | Volume: 199 | Issue: 5 | Pages: 1070-1077

10.2214/ajr.12.8637 | PMID 23096181 Get It

The Safety of Cardiopulmonary Exercise Testing in a Population With High-Risk Cardiovascular Diseases
Skalski, Joseph H. , Allison, Thomas G. , Miller, Todd D.

Mayo Clinic

Circulation | October 24, 2012 | Volume: 126 | Issue: 21 | Pages: 2465-2472

10.1161/circulationaha.112.110460 | PMID 23091065 Get It

Background— Cardiopulmonary exercise testing (CPX) with measurement of peak oxygen uptake (V o 2 ) is a powerful test for assessment and quantification of functional impairment resulting from cardiovascular disease. The safety of CPX has been established in patients with coronary artery disease and congestive heart failure, but clinical use of CPX in other cardiac diseases has been limited, in part because of a paucity of safety data. This study investigates the safety of CPX in a heterogeneous cohort of patients with a wide variety of underlying high-risk cardiac diagnoses. Methods and Results— This single-center retrospective review examined 5060 CPX studies performed in 4250 unique patients, including 1748 (35%) female subjects and 686 (14%) subjects aged ≥75 years. The primary end point was major adverse event during stress testing. The study population included patients with a variety of high-risk cardiac diseases, including congestive heart failure (n=1289, 25.5%), hypertrophic cardiomyopathy (n=598, 11.8%), pulmonary hypertension (n=194, 3.8%), and aortic stenosis (n=212, 4.2%). This patient population generally had severe functional impairment, including 1192 (24%) patients with peak V o 2 <14 mL/kg/min. Eight adverse events occurred during CPX, for an adverse event rate of 0.16%. The most common adverse event (n=6) was sustained ventricular tachycardia. There were no fatal events. Conclusions— CPX is generally a safe procedure, even in a population with underlying high-risk cardiovascular diagnoses.
Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
Karp, Judith E. , Thomas, B M , Greer, Jacqueline M., Sorge, Christopher L., Gore, Steven D. , Pratz, Keith W. , Flatten, Karen S., Peterson, Kevin, Schneider, Paula A., Mackey, Karen, Freshwater, Tomoko, McDevitt, Michael A. , Gladstone, Douglas E. , Showel, Margaret M. , Loechner, Sabine, Horowitz, Jo Ann, Isaacs, Randi , Smith, B. Douglas , Levis, Mark J. , Carraway, Hetty E. , Parry, David , Kaufmann, Scott H.

Mayo Clinic

Clinical Cancer Research | October 24, 2012 | Volume: 18 | Issue: 24 | Pages: 6723-6731

10.1158/1078-0432.ccr-12-2442 | PMID 23092873 Get It

Abstract Purpose: Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced S-phase arrest and enhances cytarabine cytotoxicity in acute leukemia cell lines and leukemic blasts in vitro. To extend these findings to the clinical setting, we have conducted a phase I study of cytarabine and SCH 900776. Experimental Design: Twenty-four adults with relapsed and refractory acute leukemias received timed sequential, continuous infusion cytarabine 2 g/m2 over 72 hours (667 mg/m2/24 hours) beginning on day 1 and again on day 10. SCH 900776 was administered as a 15- to 30-minute infusion on days 2, 3, 11, and 12. The starting dose of SCH 900776 was 10 mg/m2/dose. Results: Dose-limiting toxicities consisting of corrected QT interval prolongation and grade 3 palmar-plantar erythrodysesthesia occurred at 140 mg flat dosing (dose level 5, equivalent to 80 mg/m2). Complete remissions occurred in 8 of 24 (33%) patients, with 7 of 8 at 40 mg/m2 or higher. SCH 900776 did not accumulate at any dose level. Marrow blasts obtained pretreatment and during therapy showed increased phosphorylation of H2Ax after SCH 900776 beginning at 40 mg/m2, consistent with unrepaired DNA damage. Conclusions: These data support a randomized phase II trial of cytarabine +/− SCH 900776 at a recommended flat dose of 100 mg (equivalent to 56 mg/m2) for adults with poor-risk leukemias. The trial (SP P05247) was registered at www.clinicaltrials.gov as NCT00907517. Clin Cancer Res; 18(24); 6723–31. ©2012 AACR.
Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
Brauch, Hiltrud , Schroth, Werner , Mürdter, Thomas E. , Winter, Stefan , Schwab, Matthias , Eichelbaum, Michel , Goetz, Matthew P. , Ingle, James N. , Brauch, Hiltrud , Schwab, Matthias

Mayo Clinic

Journal of Clinical Oncology | October 23, 2012 | Volume: 31 | Issue: 2 | Pages: 176-180

10.1200/jco.2012.44.6625 | PMID 23091108 Get It

IgG4‐related prostatitis: A rare cause of steroid‐responsive obstructive urinary symptoms
Hart, Phil A. , Smyrk, Thomas C. , Chari, Suresh T. , Chari, Suresh T

Mayo Clinic

International Journal of Urology | October 18, 2012 | Volume: 20 | Issue: 1 | Pages: 132-134

10.1111/j.1442-2042.2012.03194.x | PMID 23075137 Get It

AbstractIgG4‐related disease is an idiopathic, systemic fibroinflammatory disease that can affect a wide variety of sites, including several in the genitourinary system. We describe a patient with steroid‐responsive urinary symptoms and an abnormal digital rectal exam that were secondary to IgG4‐related prostatitis. We discuss the importance of recognizing this condition and differentiating it from prostate cancer, which can present similarly.
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Emanuel, Robyn M., Dueck, Amylou C. , Geyer, Holly L. , Kiladjian, Jean‐Jacques , Slot, Stefanie , Boekhorst, Peter A.W. te , Commandeur, Suzan, Schouten, Harry C. , Sackmann, Federico, Fuentes, Ana Kerguelen, Hernández‐Maraver, Dolores , Pahl, Heike L. , Grießhammer, Martin , Stegelmann, Frank , Doehner, Konstanze, Lehmann, Thomas , Bonatz, Karin, Reiter, Andreas , Boyer, Françoise, Étienne, Gabriel , Ianotto, Jean‐Christophe , Ranta, Dana, Roy, Lydia , Cahn, Jean‐Yves, Harrison, Claire , Radia, Deepti , Muxí, Pablo , Besses, Carlos , Cervantes, Francisco , Johansson, Peter , Barbui, Tiziano , Passamonti, Francesco , Andréasson, Björn , Ferarri, Maria L, Rambaldi, Alessandro , Samuelsson, Jan , Birgegård, Gunnar , Tefferi, Ayalew , Zweegman, Sonja , Maldonado, Norman D. , Barosi, Giovanni , Vannucchi, Alessandro M. , Mesa, Ruben A. , Dueck, A. C. , Kiladjian, Jean-Jacques , Rambaldi, Alessandro , Ianotto, Jean-Christophe , Passamonti, Francesco

Mayo Clinic

Journal of Clinical Oncology | October 16, 2012 | Volume: 30 | Issue: 33 | Pages: 4098-4103

10.1200/jco.2012.42.3863 | PMID 23071245 Get It

Purpose Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.
Klf10 inhibits IL‐12p40 production in macrophage colony‐stimulating factor‐induced mouse bone marrow‐derived macrophages
Zhang, Wei , Wang, Xuelian , Xia, Xiaoping, Suo, Shanshan, Guo, Jing , Cao, Wenqiang , Cai, Zhijian , Hui, Zhaoyuan , Subramaniam, Malayannan , Spelsberg, Thomas C., Wang, Jianli , Wang, Lie , Liu, Xia , Li, Min , Cao, Wenqiang

Mayo Clinic

European Journal of Immunology | October 12, 2012 | Volume: 43 | Issue: 1 | Pages: 258-269

10.1002/eji.201242697 | PMID 23065757 Get It

Bone marrow‐derived macrophages (BMMs) treated with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) or macrophage colony‐stimulating factor (M‐CSF), differentiate into GM‐CSF‐induced mouse bone marrow‐derived macrophages (GM‐BMMs) or M‐CSF‐induced mouse bone marrow‐derived macrophages (M‐BMMs), which have an M1 or M2 profile, respectively. GM‐BMMs produce large amounts of proinflammatory cytokines and mediate resistance to pathogens, whereas M‐BMMs produce antiinflammatory cytokines that contribute to tissue repair and remodeling. M‐BMMs stimulated with lipopolysaccharide (LPS) are in an antiinflammatory state, with an IL‐12lowIL‐10high phenotype. However, the regulation of this process remains unclear. Klf10 belongs to the family of Krüppel‐like transcription factors and was initially described as a TGF‐β inducible early gene 1. IL‐12p40 is upregulated in LPS‐stimulated M‐BMMs from Klf10‐deficient mice, but downregulated during Klf10 overexpression. Klf11, another member of the Krüppel‐like factor family, can also repress the production of IL‐12p40. Furthermore, Klf10 binds to the CACCC element of the IL‐12p40 promoter and inhibits its transcription. We have therefore identified Klf10 as a transcription factor that regulates the expression of IL‐12p40 in M‐BMMs.
A Two-Stage Evaluation of Genetic Variation in Immune and Inflammation Genes with Risk of Non-Hodgkin Lymphoma Identifies New Susceptibility Locus in 6p21.3 Region
Cerhan, James R. , Fredericksen, Zachary S., Novak, Anne J. , Ansell, Stephen M. , Liebow, Mark , Cunningham, Julie M. , Wang, Alice H., Asmann, Yan W. , Kay, Neil E. , Doǧan, Ahmet , Witzig, Thomas E. , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 8, 2012 | Volume: 21 | Issue: 10 | Pages: 1799-1806

10.1158/1055-9965.epi-12-0696 | PMID 22911334 Get It

Abstract Background: Non-Hodgkin lymphoma (NHL) is a malignancy of lymphocytes, and there is growing evidence for a role of germline genetic variation in immune genes in NHL etiology. Methods: To identify susceptibility immune genes, we conducted a 2-stage analysis of single-nucleotide polymorphisms (SNP) from 1,253 genes using the Immune and Inflammation Panel. In Stage 1, we genotyped 7,670 SNPs in 425 NHL cases and 465 controls, and in Stage 2 we genotyped the top 768 SNPs on an additional 584 cases and 768 controls. The association of individual SNPs with NHL risk from a log-additive model was assessed using the OR and 95% confidence intervals (CI). Results: In the pooled analysis, only the TAP2 coding SNP rs241447 (minor allele frequency = 0.26; Thr655Ala) at 6p21.3 (OR = 1.34, 95% CI 1.17–1.53) achieved statistical significance after accounting for multiple testing (P = 3.1 × 10−5). The TAP2 SNP was strongly associated with follicular lymphoma (FL, OR = 1.82, 95%CI 1.46–2.26; p = 6.9 × 10−8), and was independent of other known loci (rs10484561 and rs2647012) from this region. The TAP2 SNP was also associated with diffuse large B-cell lymphoma (DLBCL, OR = 1.38, 95% CI 1.08–1.77; P = 0.011), but not chronic lymphocytic leukemia (OR = 1.08; 95% CI 0.88–1.32). Higher TAP2 expression was associated with the risk allele in both FL and DLBCL tumors. Conclusion: Genetic variation in TAP2 was associated with NHL risk overall, and FL risk in particular, and this was independent of other established loci from 6p21.3. Impact: Genetic variation in antigen presentation of HLA class I molecules may play a role in lymphomagenesis. Cancer Epidemiol Biomarkers Prev; 21(10); 1799–806. ©2012 AACR.
Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea
Vázquez‐Roque, María I. , Camilleri, Michael , Smyrk, Thomas C. , Murray, Joseph A. , O’Neill, Jessica, Carlson, Paula, Lamsam, Jesse, Eckert, Deborah J., Janzow, Denise, Burton, Duane, Ryks, Michael, Rhoten, Deborah, Zinsmeister, Alan R., Murray, J A

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | October 5, 2012 | Volume: 303 | Issue: 11 | Pages: G1262-G1269

10.1152/ajpgi.00294.2012 | PMID 23042942 Get It

Patients with irritable bowel syndrome (IBS) with diarrhea (IBS-D) carrying human leukocyte antigen (HLA)-DQ2/8 genotypes benefit from gluten withdrawal. Our objective was to compare gastrointestinal barrier function, mucosal inflammation, and transit in nonceliac IBS-D patients and assess association with HLA-DQ2/8 status. In 45 IBS-D patients who were naive to prior exclusion of dietary gluten, we measured small bowel (SB) and colonic mucosal permeability by cumulative urinary lactulose and mannitol excretion (0–2 h for SB and 8–24 h for colon), inflammation on duodenal and rectosigmoid mucosal biopsies (obtained in 28 of 45 patients), tight junction (TJ) protein mRNA and protein expression in SB and rectosigmoid mucosa, and gastrointestinal and colonic transit by validated scintigraphy. SB mucosal biopsies were stained with hematoxylin-eosin to assess villi and intraepithelial lymphocytes, and immunohistochemistry was used to assess CD3, CD8, tryptase, and zonula occludens 1 (ZO-1); colonic biopsy intraepithelial lymphocytes were quantitated. Associations of HLA-DQ were assessed using Wilcoxon's rank-sum test. Relative to healthy control data, we observed a significant increase in SB permeability ( P < 0.001), a borderline increase in colonic permeability ( P = 0.10), and a decrease in TJ mRNA expression in rectosigmoid mucosa in IBS-D. In HLA-DQ2/8-positive patients, ZO-1 protein expression in the rectosigmoid mucosa was reduced compared with that in HLA-DQ2/8-negative patients and colonic transit was slower than in HLA-DQ2/8-negative patients. No other associations with HLA genotype were identified. There is abnormal barrier function (increased SB permeability and reduced mRNA expression of TJ proteins) in IBS-D relative to health that may be, in part, related to immunogenotype, given reduced ZO-1 protein expression in rectosigmoid mucosa in HLA-DQ2/8-positive relative to HLA-DQ2/8-negative patients.
Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study
Silberstein, Stephen D., Saper, Joel R., Huh, Billy , Sharan, Ashwini , Reed, K. L. , Mogilner, Alon Y. , Goldstein, Jerome , Trentman, Terrence L. , Vaisman, Julien, Ordia, Joseph, Weber, Peter, Levy, Robert M. , Diaz, Roni L, Washburn, Stephanie N., Dodick, David W. , Slavin, Konstantin V. , Narouze, Samer , Weber, Peter, Deer, Timothy R. , Diaz, Roni L., Mekhail, Nagy

Mayo Clinic

Cephalalgia | October 4, 2012 | Volume: 32 | Issue: 16 | Pages: 1165-1179

10.1177/0333102412462642 | PMID 23034698 Get It

Background: Chronic migraine (CM) is a debilitating neurological disorder with few treatment options. Peripheral nerve stimulation (PNS) of the occipital nerves is a potentially promising therapy for CM patients. Methods: In this randomized, controlled multicenter study, patients diagnosed with CM were implanted with a neurostimulation device near the occipital nerves and randomized 2:1 to active ( n = 105) or sham ( n = 52) stimulation. The primary endpoint was a difference in the percentage of responders (defined as patients that achieved a ≥50% reduction in mean daily visual analog scale scores) in each group at 12 weeks. Results: There was not a significant difference in the percentage of responders in the Active compared with the Control group (95% lower confidence bound (LCB) of −0.06; p = 0.55). However, there was a significant difference in the percentage of patients that achieved a 30% reduction ( p = 0.01). Importantly, compared with sham-treated patients, there were also significant differences in reduction of number of headache days (Active Group = 6.1, baseline = 22.4; Control Group = 3.0, baseline = 20.1; p = 0.008), migraine-related disability ( p = 0.001) and direct reports of pain relief ( p = 0.001). The most common adverse event was persistent implant site pain. Conclusion: Although this study failed to meet its primary endpoint, this is the first large-scale study of PNS of the occipital nerves in CM patients that showed significant reductions in pain, headache days, and migraine-related disability. Additional controlled studies using endpoints that have recently been identified and accepted as clinically meaningful are warranted in this highly disabled patient population with a large unmet medical need. Trial registration: Clinical trials.gov (NCT00615342).